Q&A on practical aspects related to the implementation of the gradual roll-out of Eudamed pursuant to the MDR and IVDR, as amended by Regulation (EU) 2024/1860 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, the obligation to inform in case of interruption or discontinuation of supply, and transitional provisions for certain in vitro diagnostic medical devices
News & Trends
Procurar
Recentes
- FDA Guidance for Drug Development
- Study supporting the monitoring of the availability of medical devices on the EU market. 2 July 2026
- IMDRF Technical Framework for Artificial Intelligence Life Cycle Management” (IMDRF AIML WG N93 – April 2026)
- GMP CANÁBIS 2026 : “Formação conduzida com profundo domínio teórico e prático “
- MHRA Open consultation Draft rare disease therapies regulatory framework
- EU Delegated Acts on Well-Established Technologies (WET) under the MDR
- CLINICAL TRIALS: EMA CTIS Sponsor Handbook
- Update to EU GMP Guidelines – Revised Annex 19 on Reference and Retention Samples